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Background:  The universal definition of myocardial infarction provides the criteria for the diagnosis and classification of the type of acute 
myocardial infarction (AMI), and recommends the measurement of cardiac troponin (cTn). Despite this, many institutions still employ creatinine 
kinase (CK-MB) as part of standard laboratory evaluation for AMI. The aim of this study was to ascertain the cost benefit of utilizing only the cTn for 
the diagnosis of acute coronary syndrome (ACS).
Methods:  A survey was done of area hospitals and the University Hospital Consortium list serve for comparison of whether or not other institutions 
use one or both biomarkers. After initiating medical staff education our standard order sets were changed to use only cTnI for the assessment of 
AMI. The cost savings by eliminating the CK-MB on the order sets was based on the annual volume of processed specimens. The cost of the supplies, 
equipment and materials was determined on a per test basis.
Results:  After initiation of the new standard order sets, the CK-MB testing rate decreased to less than 50 per month from 1,098, giving an 
annualized savings of $82,894. Locally 75% of the responding hospitals in Kansas City use both biomarkers for the diagnosis of AMI and 57% of the 
responding university hospitals use both markers.
Conclusion: As the health care system is challenged to improve care while containing cost, the use of a single biomarker (cTn) in the diagnosis of 
AMI fulfills this promise without sacrificing patient care. 
